Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Mol Pharmacol
2011 Dec 01;806:1085-95. doi: 10.1124/mol.111.074989.
Show Gene links
Show Anatomy links
Elucidating the molecular basis of action of a classic drug: guanidine compounds as inhibitors of voltage-gated potassium channels.
Kalia J
,
Swartz KJ
.
???displayArticle.abstract???
Guanidine and its alkyl analogs stimulate the neuromuscular junction presynaptically by inhibiting voltage-gated potassium (Kv) channels, leading to enhanced release of acetylcholine in the synaptic cleft. This stimulatory effect of guanidine underlies its use in the therapy for the neuromuscular diseases myasthenic syndrome of Lambert-Eaton and botulism. The therapeutic use of guanidine is limited, however, because of side effects that accompany its administration. Therefore, the design of guanidine analogs with improved therapeutic indices is desirable. Progress toward this goal is hindered by the lack of knowledge of the mechanism by which these molecules inhibit Kv channels. Here we examine an array of possible mechanisms, including charge screening, disruption of the protein-lipid interfaces, direct interaction with the voltage sensors, and pore-binding. Our results demonstrate that guanidines bind within the intracellular pore of the channel and perturb a hydrophobic subunit interface to stabilize a closed state of the channel. This mechanism provides a foundation for the design of guanidine analogs for the therapeutic intervention of neuromuscular diseases.
Aggarwal,
Contribution of the S4 segment to gating charge in the Shaker K+ channel.
1996, Pubmed,
Xenbase
Aggarwal,
Contribution of the S4 segment to gating charge in the Shaker K+ channel.
1996,
Pubmed
,
Xenbase
Armstrong,
A model for 4-aminopyridine action on K channels: similarities to tetraethylammonium ion action.
2001,
Pubmed
Batulan,
An intersubunit interaction between S4-S5 linker and S6 is responsible for the slow off-gating component in Shaker K+ channels.
2010,
Pubmed
Benoit,
Interactions of guanidine and a related compound with potassium channels in frog myelinated nerve fibre.
1993,
Pubmed
Blumhardt,
Guanidine treatment and impaired renal function in the Eaton-Lambert syndrome.
1977,
Pubmed
Caballero,
Molecular docking study of the binding of aminopyridines within the K+ channel.
2007,
Pubmed
Chalk,
Medical treatment for botulism.
2011,
Pubmed
Farley,
Stimulation of transmitter release by guanidine derivatives.
1979,
Pubmed
Green,
Surface charges and ion channel function.
1991,
Pubmed
Hauser,
4-aminopyridine: new life for an old drug.
2010,
Pubmed
Holmgren,
Trapping of organic blockers by closing of voltage-dependent K+ channels: evidence for a trap door mechanism of activation gating.
1997,
Pubmed
Hoshi,
Biophysical and molecular mechanisms of Shaker potassium channel inactivation.
1990,
Pubmed
,
Xenbase
Jiang,
X-ray structure of a voltage-dependent K+ channel.
2003,
Pubmed
Jiang,
The principle of gating charge movement in a voltage-dependent K+ channel.
2003,
Pubmed
Keogh,
Treatment for Lambert-Eaton myasthenic syndrome.
2011,
Pubmed
Kumble,
Inorganic polyphosphate in mammalian cells and tissues.
1995,
Pubmed
Liu,
Gated access to the pore of a voltage-dependent K+ channel.
1997,
Pubmed
Long,
Voltage sensor of Kv1.2: structural basis of electromechanical coupling.
2005,
Pubmed
Long,
Atomic structure of a voltage-dependent K+ channel in a lipid membrane-like environment.
2007,
Pubmed
Lu,
Coupling between voltage sensors and activation gate in voltage-gated K+ channels.
2002,
Pubmed
,
Xenbase
Lu,
Ion conduction pore is conserved among potassium channels.
2001,
Pubmed
Lundh,
The mode of action of 4-aminopyridine and guanidine on transmitter release from motor nerve terminals.
1977,
Pubmed
López-Barneo,
Effects of external cations and mutations in the pore region on C-type inactivation of Shaker potassium channels.
1993,
Pubmed
,
Xenbase
Mayorov,
Symptomatic relief of botulinum neurotoxin/a intoxication with aminopyridines: a new twist on an old molecule.
2010,
Pubmed
,
Xenbase
Perozo,
Gating currents from a nonconducting mutant reveal open-closed conformations in Shaker K+ channels.
1993,
Pubmed
Ramu,
Enzymatic activation of voltage-gated potassium channels.
2006,
Pubmed
Schmidt,
Phospholipids and the origin of cationic gating charges in voltage sensors.
2006,
Pubmed
Seoh,
Voltage-sensing residues in the S2 and S4 segments of the Shaker K+ channel.
1996,
Pubmed
,
Xenbase
Shieh,
Mutational analysis of ion conduction and drug binding sites in the inner mouth of voltage-gated K+ channels.
1994,
Pubmed
Stefani,
Gating of Shaker K+ channels: I. Ionic and gating currents.
1994,
Pubmed
,
Xenbase
Sukhareva,
Constitutive activation of the Shaker Kv channel.
2003,
Pubmed
,
Xenbase
Swartz,
Sensing voltage across lipid membranes.
2008,
Pubmed
Webster,
Intracellular gate opening in Shaker K+ channels defined by high-affinity metal bridges.
2004,
Pubmed
Wulff,
K+ channel modulators for the treatment of neurological disorders and autoimmune diseases.
2008,
Pubmed
Xu,
Removal of phospho-head groups of membrane lipids immobilizes voltage sensors of K+ channels.
2008,
Pubmed
,
Xenbase
Yellen,
The voltage-gated potassium channels and their relatives.
2002,
Pubmed
Zacharias,
Cation-pi interactions in ligand recognition and catalysis.
2002,
Pubmed
Zhang,
Differential effects of S6 mutations on binding of quinidine and 4-aminopyridine to rat isoform of Kv1.4: common site but different factors in determining blockers' binding affinity.
1998,
Pubmed
,
Xenbase
del Camino,
Tight steric closure at the intracellular activation gate of a voltage-gated K(+) channel.
2001,
Pubmed
del Camino,
Status of the intracellular gate in the activated-not-open state of shaker K+ channels.
2005,
Pubmed
,
Xenbase
